JP2006510669A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510669A5
JP2006510669A5 JP2004559315A JP2004559315A JP2006510669A5 JP 2006510669 A5 JP2006510669 A5 JP 2006510669A5 JP 2004559315 A JP2004559315 A JP 2004559315A JP 2004559315 A JP2004559315 A JP 2004559315A JP 2006510669 A5 JP2006510669 A5 JP 2006510669A5
Authority
JP
Japan
Prior art keywords
composition
age
patient
group
compound selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004559315A
Other languages
English (en)
Other versions
JP2006510669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038678 external-priority patent/WO2004052227A2/en
Publication of JP2006510669A publication Critical patent/JP2006510669A/ja
Publication of JP2006510669A5 publication Critical patent/JP2006510669A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 患者における加齢性黄斑変性、糖尿病性網膜症、および／または網膜浮腫を処置するための組成物であって、薬学的に効果的な量の以下：
    Figure 2006510669
     からなる群より選択される化合物を含む、組成物。
JP2004559315A 2002-12-06 2003-12-05 眼障害および眼疾患の処置のためのスーパーオキシドジスムターゼ模倣物 Pending JP2006510669A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43140102P 2002-12-06 2002-12-06
PCT/US2003/038678 WO2004052227A2 (en) 2002-12-06 2003-12-05 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Publications (2)

Publication Number Publication Date
JP2006510669A JP2006510669A (ja) 2006-03-30
JP2006510669A5 true JP2006510669A5 (ja) 2006-08-24

Family

ID=32507723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004559315A Pending JP2006510669A (ja) 2002-12-06 2003-12-05 眼障害および眼疾患の処置のためのスーパーオキシドジスムターゼ模倣物

Country Status (9)

Country Link
US (2) US20060089343A1 (ja)
EP (1) EP1581212A4 (ja)
JP (1) JP2006510669A (ja)
CN (1) CN1717234A (ja)
AU (1) AU2003298917A1 (ja)
BR (1) BR0317026A (ja)
CA (1) CA2505608A1 (ja)
MX (1) MXPA05005240A (ja)
WO (1) WO2004052227A2 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
JP2008515778A (ja) * 2004-08-18 2008-05-15 シリオン セラピューティクス， インコーポレイテッド 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
US20060252107A1 (en) * 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
CN101686665B (zh) 2007-04-20 2014-04-23 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
BRPI0812755A2 (pt) 2007-06-29 2014-09-30 Acucela Inc Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
CN101889017B (zh) 2007-10-05 2013-11-27 奥克塞拉有限公司 用于治疗疾病的烷氧基化合物
WO2009096905A1 (en) * 2008-01-30 2009-08-06 Agency For Science, Technology And Research Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
US20110028513A1 (en) * 2008-03-31 2011-02-03 Lang Zhuo Method for treating neurological disorders with imidazolium and imidazolinium compounds
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
EP3536317A1 (en) 2009-10-30 2019-09-11 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
PT2433640T (pt) 2010-09-24 2020-04-03 Omnivision Gmbh Composição compreendendo sod, luteína e zeaxantina
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
EP3689342A1 (en) 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
EP2701695B1 (en) 2011-04-26 2019-04-03 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
EP2701696B1 (en) 2011-04-26 2020-06-03 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
EP2804605A4 (en) 2012-01-20 2015-07-08 Acucela Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
WO2014064697A1 (en) * 2012-10-25 2014-05-01 Technion Research And Development Foundation Ltd. Method of treatment of disease
EP2970099A4 (en) 2013-03-12 2016-12-21 Acucela Inc SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF EYE DISEASES AND DRESSES
CN113214084A (zh) 2015-11-23 2021-08-06 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
CN116438187A (zh) 2020-02-21 2023-07-14 拜奥吉瓦有限责任公司 多不饱和脂肪酸及其衍生物的同位素修饰方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
ES2198767T3 (es) * 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
GB9817845D0 (en) * 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
JP4501128B2 (ja) * 1999-01-25 2010-07-14 ナショナル ジュウィッシュ ヘルス 置換ポルフィリン
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance

Similar Documents

Publication Publication Date Title
JP2006510669A5 (ja)
JP2008540528A5 (ja)
JP2003503454A5 (ja)
MXPA03007590A (es) Composiciones y metodos para mejorar suministro de droga a traves de y dentro de tejidos oculares.
JP2007537301A5 (ja)
JP2005518433A5 (ja)
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
HUS1500021I1 (hu) 1,2,4-oxadiazol-benzoesav vegyületek és alkalmazásuk nonszensz szupresszióra és a betegség kezelésére
DE69918296D1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
JP2005537234A5 (ja)
WO2008008433A3 (en) Substituted acylanilides and methods of use thereof
JP2005518413A5 (ja)
ATE482708T1 (de) Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen
JP2008516000A5 (ja)
WO2006128125A3 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
DK1864668T3 (da) Anvendelse af prodrug til okulær, intravitreal administration
WO2007030944A3 (en) Methods of cardioprotection using dichloroacetate in combination with an inotrope
JP2020531511A5 (ja)
WO2007019575A3 (en) Methods for treating b-cell malignancies using taci-ig fusion molecule
JP2004527469A5 (ja)
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
EP1631306A4 (en) COMPOSITIONS AND METHODS OF TREATING AND PREVENTING HEART TISSUE DEGENERATION AND THEIR USE